During the corresponding time, Cytomx Therapeutics Inc saw a revenue deteriorated by -92.4 % year on year, sequentially revenue fell by -86.18 %. While revenue at the Cytomx Therapeutics Inc 's corporate clients
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a pioneering company in the sphere of masked, conditionally activated biologic therapeutics, has recently achieved significant milestones that underscore its innovative prowess in the field of oncology. Notably, their latest advancements include the dosing of the first patient with their novel therapeutic candidate, CX-801, as well as the nomination of a second clinical candidate in their strategic PROBODY T-Cell Engaging Bispecific (TCB) collaboration with Astellas Pharma Inc. Together, these developments highlight the company’s continued commitment to advancing cancer treatment modalities and improving patient outcomes. CX-801: A Promising Novel Therapeutic Avenu...
CSIMarket.com reports significant advancement in cancer therapeutics with CytomX Therapeutics confirming critical initial Phase 1a dose escalation data for the monotherapy CX-904, an EGFRxCD3 PROBODY T-cell engager. This progress signifies a vital phase in the transition and evaluation of this innovative candidate treatment from laboratory to clinical trials. CX-904 demonstrated an overall favorable safety profile across the step-dosing cohorts studied in the Phase 1a dose escalation stage. Notably, no signs of cytokine release syndrome (CRS) of any severity were noted in the step-dosing cohorts under scrutiny. Additionally, the therapy illustrated no incidences of CRS exceeding grade 1, further supporting ...
CytomX Therapeutics, a renowned biotechnology company specializing in developing transformative antibody-drug conjugates, has recently announced its 2024 priorities and milestones. By aligning their focus on cutting-edge research and development, the company is poised to make significant advances in the field of cancer therapeutics.One of the most promising endeavors undertaken by CytomX Therapeutics is the advancement of CX-904 (EGFRxCD3 T-cell engager) into Phase 1a dose escalation. This innovative therapy brings together the benefits of both immune cells and T-cell engagement, targeting the epidermal growth factor receptor (EGFR). Anticipated to deliver initial data in the second half of 2024, the outcome...
Sources:
Cytomx Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cytomx Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cytomx Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
